Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...
Thomas Durcan’s project will dissect the role of microglia in degenerative conditions, to identify new therapeutic strategies for Alzheimer's treatment...
This workshop is organized by Dr. Pedro Rosa-Neto, MD, PhD, from The Douglas Research Centre, McGill University, and The Neuro.3801 rue University, Montreal, QC, H3A 2B4, CA/neuroCategory: Academic...
Diagnosis of dementia is still a major challenge globally, with an estimated 75% of cases still going undiagnosed and long wait times./medsimcentreCategory: Medicine and Health Sciences...
U.S. government health officials approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been...
Join us as Claire Webster interviews Dr. Serge Gauthier and Dr. José Morais./medsimcentreCategory: Medicine and Health Sciences
Medical Simulation Centre
Join us on October 7 at noon for the next webcast in our weekly series, McGill Cares, designed to support informal careg/medsimcentreCategory: Medicine and Health Sciences
Medical Simulation Centre
New research from McGill University has found that the presence and severity of mild behavioural impairment (MBI) in cognitively healthy individuals is strongly associated with the presence of...
RSS